July 11, 2010

TriVascular Secures Funding to Support Clinical Activities

July 12, 2010—TriVascular, Inc. (Santa Rosa, CA) announced the close of $60 million in financing that will be used to launch the company's Ovation abdominal stent graft system in Europe, as well as support clinical research and fund next-generation product development. The financing was composed of a Series C equity financing and growth capital venture debt. The company is completing a clinical study in Germany and has begun its pivotal study in the United States. Clinical activity is also underway for the Ovation thoracic stent graft system. The Ovation abdominal stent graft system is an investigational device and is currently not approved for sale, the company advised.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

July 11, 2010

TriVascular Secures Funding to Support Clinical Activities

Current Issue

Keep In Touch